Hunt NB, Pajouheshnia R, Salih A, van Doorn S, Souverein PC, Bazelier MT, Klungel OH, Gardarsdottir H. Prescribing of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands. Br J Clin Pharmacol. 2023 Jul;89(7):2263-71. doi: 10.1111/bcp.15708
van den Dries CJ, Pajouheshnia R, van den Ham HA, Souverein P, Moons KGM, Hoes AW, Geersing GJ, van Doorn S. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Br J Clin Pharmacol. 2023 Feb;89(2):751-61. doi: 10.1111/bcp.15534
Gemmeke M, Koster ES, Pajouheshnia R, Kruijtbosch M, Taxis k, Bouvy ML. Using pharmacy dispensing data to predict falls in older individuals. Br J Clin Pharmacol. 2021 Mar;87(3):1282-90. doi: 10.1111/bcp.14506
Weatherall M, Aantaa R, Conti G, Garratt CJ, Pohjanjousi P, Lewis MA, Moore N, Perez-Gutthann S. A multinational, drug utilisation study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU. Br J Clin Pharmacol. 2017 Sep;83(9):2066-76. doi: 10.1111/bcp.13293
Schmiedl S, Fischer R, Ibanez L, Fortuny J, Thurmann P, Ballarin E, Ferrer P, Sabate M, Rottenkolber D, Gerlach R, Tauscher M, Reynolds R, Hasford J, Rottenkolber M. Tiotropium Respimat® vs. HandiHaler®: real-life usage and TIOSPIR trial generalizability. Br J Clin Pharmacol. 2016 Feb;81(2):379-88. doi: 10.1111/bcp.12808
Williams VS, Nelson LM, Fehnel SE, MacDougall J, Carson RT, Tourkodimitris S, Kurtz C, Baird MJ, Johnston JM. Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014 Aug;40(3):298-308. doi: 10.1111/apt.12830
Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May;39(10):1143-55. doi: 10.1111/apt.12727
Godwin SL, Coppings R, Kosa KM, Cates SC. Consumer response to food contamination and recalls: findings from a national survey. J Food Distrib Res. 2012 Mar;43(1):19-26. doi: 10.22004/ag.econ.139445
Huerta C, Rivero E, Montoro MA, García-Rodriguez LA. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study. Aliment Pharmacol Ther. 2011 Apr;33(8):969-78. doi: 10.1111/j.1365-2036
Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.
Feltner D, Hill C, Lenderking W, Williams VS, Morlock R. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial. J Psychiatr Res. 2009 Oct;43(15):1224-30.
Morlock RJ, Williams VS, Cappelleri JC, Harness J, Fehnel SE, Endicott J, Feltner D. Development and evaluation of the Daily Assessment of Symptoms – Anxiety (DAS-A) Scale to evaluate onset of symptom relief in patients with generalized anxiety disorder. J Psychiatr Res. 2008 Oct;42(12):1024-36.
Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008 Jun 15;27(12):1224-32.
Tennis P, Andrews E, Hickman P, Miller D, Hollis KA, Cook S. The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Aliment Pharmacol Ther. 2007 Feb 1;25(3):317-22.
Miller DP, Bennett L, Hollis KA, Tennis P, Cook SF, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.
Mangel AW, Fehnel SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther. 2005 Dec 1;22(11-12):1162-3.
Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen VZ, Hamm LR, Mangel AW, Tennis P, Cook SF. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005 Nov 10;22:935-42.
Vakil N, Hahn B, McSorley DJ. Recurrent symptoms and gastro-oesophageal reflux disease in patient with duodenal ulcer treated for helicobacter pylori infection. Aliment Pharmacol Ther. 2000 Jan;14(1):45-51.
Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol. 1999 Dec 1;48(6):847-52.
Camilleri M, Mayer EA, Drossman DA, Heath AT, Dukes GE, McSorley DJ, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.
Garcia Rodriguez LA, Perez GS. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol. 1998 May 1;45(5):419-25.
Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate (tritec) plus clarithromycin is effective for healing duodenal ulcers, eradicating h.pylori, and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10(3):251-61.